In a major healthcare reform aimed at making critical treatments affordable, the Indian government has imposed a strict maximum trade margin on 137 anti-cancer medications. Regulated by the National Pharmaceutical Pricing Authority, this policy revision has led to price drops exceeding 50 percent for over 600 brands, with some seeing cuts of up to 96 percent. Authorities estimate that these revised maximum retail prices will collectively save patients and their families approximately Rs 3,500 crore annually. Retailers, hospitals, and dealers have been instructed to display the updated pricing charts clearly across all medical institutions.
